Resveratrol inhibits proliferation, angiogenesis and induces apoptosis in colon cancer cells: Calorie restriction is the force to the cytotoxicity

Human and Experimental Toxicology

Volumn 32, Issue 10, 2013, Pages 1067-1080

  Fouad, M A ^a   Agha, A M ^a   Merzabani, Mm Al ^a   Shouman, S A ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

angiogenesis; apoptosis; calorie restriction; colorectal carcinoma; Resveratrol

Indexed keywords

CITRATE SYNTHASE; LACTATE DEHYDROGENASE; LEPTIN; MYC PROTEIN; PYRUVATE KINASE; RESVERATROL; VASCULOTROPIN;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CALORIC RESTRICTION; CANCER CELL; CANCER INHIBITION; CELL PROLIFERATION; COLON CANCER; CYTOTOXICITY; DNA FRAGMENTATION; DOWN REGULATION; ENZYME ACTIVITY; GLUCOSE INTAKE; GLYCOLYSIS; HUMAN; HUMAN CELL; IC 50; PRIORITY JOURNAL;

ANGIOGENESIS; APOPTOSIS; CALORIE RESTRICTION; COLORECTAL CARCINOMA; RESVERATROL;

ANTINEOPLASTIC AGENTS; APOPTOSIS; CACO-2 CELLS; CALORIC RESTRICTION; CELL PROLIFERATION; CITRATE (SI)-SYNTHASE; GLUCOSE; HCT116 CELLS; HUMANS; L-LACTATE DEHYDROGENASE; LEPTIN; NEOVASCULARIZATION, PHYSIOLOGIC; PROTO-ONCOGENE PROTEINS C-MYC; PYRUVATE KINASE; STILBENES; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84883467662     PISSN: 09603271     EISSN: 14770903     Source Type: Journal    
DOI: 10.1177/0960327113475679     Document Type: Article

References (71)

1. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics CA cancer. J Clin. 2008 ; 58: 71-96
2. Parkin D, Bray F Cancer epidemiology and prevention. Schottenfeld D Fraumeni J, ed. New York, NY: Oxford University Press ; 2006: 101-138.
3. Center MM, Jemal A, Ward E. International trends in colorectal cancer incidence rates. Cancer Epidemiol Biomarkers Prev. 2009 ; 18: 1688-1694
4. Hursting SD, Lashinger LM, Wheatley KW, Rogers CJ, Colbert LH, Nunez NP, et al. Reducing the weight of cancer: mechanistic targets for breaking the obesity carcinogenesis link. Clin Endocrin Metab. 2008 ; 22: 659-669
5. Komninou D, Ayonote A, Richie JP, Rigas B. Insulin resistance and its contribution to colon carcinogenesis. Exp Biol Med. 2003 ; 228: 396-405
6. Kundu JK, Surh YJ. Cancer chemopreventive and therapeutic potential of resveratrol: mechanistic perspectives. Cancer Lett. 2008 ; 269: 243-261
7. Ulrich S, Wolter F, Stein J M. Molecular mechanisms of the chemopreventive effects of resveratrol and its analogs in carcinogenesis. Mol Nutr Food Res. 2005 ; 49: 452-461
8. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov. 2006 ; 5: 493-506
9. Aziz MH, Kumar R, Ahmad N. Cancer chemoprevention by resveratrol: in vitro and in vivo studies and the underlying mechanisms. Int J Oncol. 2003 ; 23: 17-28
10. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science. 1997 ; 275: 218-220
11. Bhat KPL, Lantvit D, Christov K, Mehta RG, Moon RC, Pezzuto JM. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 2001 ; 61: 7456-7463
12. Lee JE, Safe S. Involvement of a post-transcriptional mechanism in the inhibition of CYP1A1 expression by resveratrol in breast cancer cells. Biochem Pharmacol. 2001 ; 62: 1113-1124
13. Kundu JK, Surh YJ. Molecular mechanisms underlying chemoprevention with resveratrol. Cancer Prev Res. 2005 ; 10: 89-98
14. Izard BC, Roman JC, Kern V, Mathiot C, Mentz F, Kolb JB. Comparative antiproliferative and apoptotic effects of resveratrol, epsilon-viniferin and vine-shots derived polyphenols (vineatrols) on chronic B lymphocytic leukemia cells and normal human lymphocytes. Leuk Lymphoma. 2002 ; 43: 1991-2002
15. Vichai V, Kirtikara K. Sulforhodamine B colorimetric assay for cytotoxicity screening. Nat Protoc. 2006 ; 1: 1112-1116
16. Trinder P. Determination of glucose in blood using glucose oxidase with an alternative oxygen receptor. Ann Clin Biochem. 1969 ; 6: 24-27
17. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem. 1976 ; 72: 248-254
18. Srere PA. Citrate synthase. Meth Enzymol. 1969 ; 13: 3-11
19. Malcovati M, Valentini G. AMP and fructose 1, 6-biphosphate-activated pyruvate kinases from Escherichia coli. Meth Enzymol. 1982 ; 90: 170-179
20. Dito WR Clinical enzymology. Griffiths JC, ed. New York, NY: Masson publishing, Inc ; 1979: 18.
21. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun. 1989 ; 161: 851
22. Yang H, Chen WQ, Cao X, Worschech A, Du LF, Fang WY, et al. Caveolin-1 enhances resveratrol-mediated cytotoxicity and transport in hepatocellular carcinoma model. J Transl Med. 2009 ; 7: 22
23. Joe AK, Liu H, Suzui M, Vural M E, Xiao D, Weinstein IB. Resveratrol induces growth inhibition, S-phase arrest, apoptosis, and changes in biomarker expression in several human cancer cell lines. Clin Cancer Res. 2002 ; 8: 893-903
24. Heuertz DS, Ezekiel RM, Uthayashanker R. Growth inhibition of human colon cancer cells by plant compounds. Clin Lab Sci. 2008 ; 3: 151-157
25. Schneider Y, Vincent F, Duranton B, Badolo L, Gosse ÂF, Bergmann C, et al. Anti proliferative effect of resveratrol, a natural component of grapes and wine, on human colonic cancer cells. Cancer Lett. 2000 ; 158: 85-91
26. Wolter F, Turchanowa L, Stein J. Resveratrol-induced modification of polyamine metabolism is accompanied by induction of c-Fos. Carcinogenesis. 2003 ; 24: 469-474
27. Fontcave M, Lepoivre M, Elleingand E, Gerez C, Guittet O. Resveratrol, a remarkable inhibitor of ribonucleotide reductase. FEBS Lett. 1997 ; 421: 277-279
28. Sun NJ, Woo SH, Cassady JM, Snapka RM. DNA polymerase and topoisomerase II inhibitors from Psoralea corylifolia. J Nat Prod. 1998 ; 61: 362-366
29. Warburg O. On respiratory impairment in cancer cells. Science. 1956 ; 124: 269-270
30. Polyak K, Li Y, Zhu H, Lengauer C, Willson JK, Markowitz SD, et al. Somatic mutations of the mitochondrial genome in human colorectal tumours. Nat Genet. 1998 ; 20: 291-293
31. López-Ríos F, Aragó MS, García EG, Ortega ÁD, Berrendero JR, Guez FP, et al. Loss of the mitochondrial bioenergetic capacity underlies the glucose avidity of carcinomas. Cancer Res. 2007 ; 67: 9013-9017
32. Xu R, Pelicano H, Zhou Y, Carew JS, Feng L, Bhalla KN, et al. Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. Cancer Res. 2005 ; 65: 613-621
33. Wood JG, Rogina B, Lavu S, Howitz K, Helfand SL. Sirtuin activators mimic caloric restriction and delay ageing in metazoans. Nat. 2004 ; 430: 686-689
34. Jiang W, Zhu Z, Thompson HJ. Effect of energy restriction on cell cycle machinery in 1-methyl-1-nitrosourea-induced mammary carcinomas in rats. Cancer Res. 2003 ; 63: 1228-1234
35. Chang SC, Ziegler RG, Dunn B, Stolzenberg-Solomon R, Lacey JV, Huan WY. Association of energy intake and energy balance with postmenopausal breast cancer in the prostate, lung, colorectal, and ovarian cancer screening trial. Cancer Epidemiol Biomarkers Prev. 2006 ; 15: 334-341
36. Fantin VR, St-Pierre J, Leder P. Attenuation of LDH: a expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. Cancer Cell. 2006 ; 9: 425-434
37. Zhang J. Resveratrol inhibits insulin responses in a SirT1 independent pathway. Biochem J. 2006 ; 397: 519-527
38. Kueck A, Opipari AW, Griffith KA, Tan L, Choi M, Huang J, et al. Resveratrol inhibits glucose metabolism in human ovarian cancer cells. Gynecol Oncol. 2007 ; 107: 450-457
39. Zhong D, Xiong L, Liu T, Liu X, Chen J, Sun SY, et al. The glycolytic inhibitor 2-deoxyglucose activates multiple prosurvival pathways through IGF1R. J Biol Chem. 200: 23225-23233
40. Faber AC, Dufort FJ, Blair D, Wagner D, Oberts MF, Chiles TC. Inhibition of phosphatidylinositol 3-kinase-mediated glucose metabolism coincides with resveratrol-induced cell cycle arrest in human diffuse large B-cell lymphomas. Biochem Pharmacol. 2006 ; 72: 1246-1256
41. Barger JL, Kayo T, Vann JM, Arias EB, Wang J. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One. 2008 ; 6: 2264-2273
42. Su HC, Hung LM, Chen JK. Resveratrol, a red wine antioxidant, possesses insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab. 2006 ; 290: 1339-1346
43. Fröjdö S, Christine D, Pirola L. Metabolic effects of resveratrol in mammals: a link between improved insulin action and aging. Curr Aging Sci. 2008 ; 1: 145-151
44. Vetterli L, Brun T, Giovannoni L, Bosco D, Maechler P. Resveratrol potentiates glucose stimulated insulin secretion in INS-1E ß cells and human islets through SIRT 1 dependent mechanism. J Biol Chem. 2011 ;:
45. Park CE, Kim MJ, Lee JH, Min BI, Bae H, Choe W, et al. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med. 2007 ; 39: 222-229
46. Lagouge M, Argmann C, Gerhart-Hines Z, Meziane H, Lerin C, Daussin F, et al. Resveratrol improves mitochondrial function and protects against metabolic disease by activating SIRT1 and PGC-1α. Cell. 2006 ; 127: 1109-1122
47. Chan AY, Dolinsky VW, Soltys CL, Viollet B, Baksh S, Light PE, et al. Resveratrol inhibits cardiac hypertrophy via AMP-activated protein kinase and Akt. J Biol Chem. 2008 ; 283: 24194-24201
48. Marcu KB. Bossone SA and Patel AJ. c-Myc function and regulation. Ann Rev Biochem. 1992 ; 61: 809-860
49. Shim H, Dolde C, Lewis BC, Wu CS, Dang G. Jungmann RA, et al. c-Myc transactivation of LDH-A: implications for tumor metabolism and growth. Proc Natl Acad Sci USA. 1997 ; 94: 6658-6663
50. Gardner L, Lee L, Dang C The encyclopedia of cancer. 2 nd ed. Academic Press; An imprint of Elsevier, 2002, pp. 1-13. 2002, pp. 1-13:
51. Parlo PA, Coleman PS. Continuous pyruvate carbon flux to newly synthesized cholesterol and the suppressed evolution of pyruvate-generated CO2 in tumors: further evidence for a persistent truncated Krebs cycle in hepatomas. Biochim Biophys Acta. 1986 ; 886: 169-176
52. Amemori S, Ootani A, Aoki S, Fujise T, Iwakiri R, Fujimoto K, et al. Adipocytes and preadipocytes promote the proliferation of colon cancer cells in vitro. Am J Physiol. 2007 ; 292: 923-929
53. Aloulou N, Garin SB, Le Gouvello S, Abolhassan M, Chaumette MT, Charachon A, et al. Involvement of the leptin receptor in the immune response in intestinal cancer. Cancer Res. 2008 ; 68: 9413-9422
54. Sitaraman S, Liu X, Charrier L, Gu L, Ziegler TR, Gewirtz A, et al. Colonic leptin: source of a novel pro-inflammatory cytokine involved in inflammatory bowel disease. FASEB J. 2004 ; 18: 696-698
55. Jarde T, Caldefie-Chezet F, Goncalves-Mendes N, Mishellany F, Buechler C, Penault-Llorca F, et al. Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endoc Relat Cancer. 2009 ; 16: 1197-1210
56. Szkudelska K, Nogowski L, Szkudelski T. The inhibitory effect of resveratrol on leptin secretion from rat adipocytes. Eur J Clin Invest. 2009 ; 39: 899-905
57. Rayalam S, Yang JY, Ambati S, Della-Fera MA, Baile CA. Resveratrol induces apoptosis and inhibits adipogenesis in 3T3-L1 adipocytes. Phytother Res. 2008 ; 22: 1367-1371
58. Rivera L, Moro N, Zarzuelo A, Galisteo M. Long-term resveratrol administration reduces metabolic disturbances and lowers blood pressure in obese Zucker rats. Biochem Pharm. 2009 ; 77: 1053-1063
59. Warner HR, Fernandes G, Wang E. A unifying hypothesis to explain the retardation of aging and tumorigenesis by caloric restriction. J Gerontol Biol Med Sci. 1995 ; 50: 107-109
60. Mahyar-Roemer M, Katsen A, Mestres P, Roemer K. Resveratrol induces colon tumor cell apoptosis independently of p53 and precede by epithelial differentiation, mitochondrial proliferation and membrane potential collapse. Int J Cancer. 2001 ; 94: 615-622
61. Wolter F, Akoglu B, Clausnitzer A, Stein J. Downregulation of the cyclin D1/Cdk4 complex occurs during resveratrol-induced cell cycle arrest in colon cancer cell lines. J Nutr. 2001 ; 131: 2197-2203
62. Jiang H, Zhang L, Kuo J, Kuo K, Gautam SC, Groc L, et al. Resveratrol-induced apoptotic death in human U251 glioma cells. Mol Cancer Ther. 2005 ; 4: 554-561
63. Delmas D, Rebe C, Lacour S, Filomenko R, Athias A, Gambert P, et al. Resveratrol-induced apoptosis is associated with Fas redistribution in the rafts and the formation of a death-inducing signaling complex in colon cancer cells. J Biol Chem. 2003 ; 278: 41482-41490
64. Trincheri NF, Nicotra G, Follo C, Castino R, Isidoro C. Resveratrol induces cell death in colorectal cancer cells by a novel pathway involving lysosomal cathepsin D. Carcinogenesis. 2007 ; 28: 922-931
65. Carmeliet P. Angiogenesis in life, disease and medicine. Nature. 2005 ; 438: 932-936
66. Tang Z, Liu XY, Zou P. Resveratrol inhibits the secretion of vascular endothelial growth factor and subsequent proliferation in human leukemia U937 cells. J Huazhong Univ Sci Technolog Med Sci. 2007 ; 27: 508-512
67. Cao Z, Fang J, Xia C, Shi X, Jiang BH. Trans-3,4,5 trihydroxystibene inhibits hypoxia-inducible factor 1alpha and vascular endothelial growth factor expression in human ovarian cancer cells. Clin Cancer Res. 2004 ; 10: 5253-5263
68. Garvin S, Ollinger K, Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 2006 ; 231: 113-122
69. Zhang Q, Tang X, Lu QY, Zhang ZF, Brown J, Le AD. Resveratrol inhibits hypoxia-induced accumulation of hypoxia-inducible factor-1a and VEGF expression in human tongue squamous cell carcinoma and hepatoma cells. Mol Cancer Ther. 2005 ; 4: 1465-1474
70. Chen Y, Tseng SH. Pro and anti-angiogenesis effects of resveratrol. In vivo. 2007 ; 21: 365-370
71. Kimura Y, Okuda H. Resveratrol isolated from polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J Nutr. 2001 ; 131: 1844-1849